China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China. The group has 22 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and three A-share listed companies, Beijing Tiantan Biological Products Corporation Limited (BTBP), China National Medicines Co., Ltd. (CNCM) and Shenzhen Accord Pharmaceutical Co., Ltd.. In 2009, the group’s sale revenue had reached 65 billion Yuan. Among the 129 enterprises under SASAC, SINOPHARM is ranked 50th and 38th in terms of sales revenue and total profit respectively.

In China, by possessing the first-class manufacturers for medicines, vaccines and blood products, high-level R & D institutes, a distribution network covering the whole nation, large-scale TCM plant bases and top pharmaceutical exhibitions, SINOPHARM has completed its industrial chain. Since 1980, SINOPHARM has cooperated with foreign global pharmaceutical companies and established 20 joint ventures including China Otsuka, SSPC, etc.; developed international technical cooperation projects with USA, France, Italy, Japan and Korea etc.; built up bonds of trade and cooperation with more than 100 countries or regions. Those actions effectively improve the manufacture and management level of pharmaceutical industry in China.

Under the guide of the corporate conception of ‘Caring for life, attending to health’, SINOPHARM and its subsidiaries have always undertaken the responsibility of national medical storage, allocation and emergency supply for public health emergencies disasters and epidemics. In prevention and treatment of SARS in 2003, fighting against Sichuan Earthquake in 2008 and prevention and control of A H1N1 influenza in 2009, SINOPHARM played an important role in safeguarding the public health and maintaining social stability.

SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc, and also the sponsor and supporter of many important exhibitions including PHARMCHINA.

SINOPHARM is aiming for an annual sale revenue of 100 billion Yuan in 2012 and 180 - 190 billion Yuan in 2015 and to become one of the Top 500 Global Corporations, a globally respectable pharmaceutical and healthcare group which can represent the national pharmaceutical industry level and impact the world pharmaceutical market.